2021 (v1)
Publication
No description
Uploaded on: April 14, 2023
-
-
2020 (v1)Publication
Borderline ovarian tumours (BOTs) are ovarian neoplasms characterised by epithelial proliferation, variable nuclear atypia and no evidence of destructive stromal invasion. BOTs account for approximately 15% of all epithelial ovarian cancers. Due to the fact that the majority of BOTs occur in women under 40 years of age, their surgical...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2022 (v1)Publication
Background and aim: In vulvar cancer, the standard treatment is radical local excision, with immediate reconstruction. Reconstruction aims to restore anatomy and function of the external female genitalia, facilitating preservation of normal body image, sexual function, and micturition and defecation functions. Methods: The purpose of this paper...
Uploaded on: February 14, 2024 -
2020 (v1)Publication
Tisotumab vedotin (TV) is a humanized antibody-drug conjugate (ADC) directed against tissue factor, a protein involved in signaling pathways related to angiogenesis, cell adhesion, motility and survival. It has been reported that tissue factor is aberrantly expressed by many types of solid tumors and it is associated with negative oncological...
Uploaded on: February 14, 2024 -
2020 (v1)Publication
Introduction: Patients with high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and current chemotherapy regimens for treating advanced disease are far from satisfactory. Prexasertib (LY2606368) is a novel checkpoint kinase inhibitor (CHK) under investigation for the treatment of HGSOC. Data from a recent phase II trial showed...
Uploaded on: April 14, 2023